Thursday, 28 September 2023



LATEST NEWS Mohammad Aijaz Asad Holds Meeting with Diverse Political Party Delegates Rajeev Rai Bhatnagar Emphasizes Collaborative Efforts to Combat Rabies Impact Health Minister Dr. Dhani Ram Shandil launches 'Tele MANAS', a mental health care service Chief Minister Bhagwant Singh Mann Vows To Realise Dream Of Bhagat Singh By Making Punjab Frontrunner In Country Feel My Love: A Mesmerising Visual Treat Of Love, Celebrating Intense On-Screen Chemistry Of Diljit Dosanjh & Elva Saleh Anmol Gagan Mann Inaugurates Three-Day Inquilab Festival In Khatkar Kalan SIT has evidence, Sukhpal Khaira has been involved in drug smuggling - Malvinder Singh Kang Urvashi Rautela Gets Spotted In A Uber Cool Look With Her Fendi X Versace Fendance Tote Bag Worth Rs 5.5 Lakhs At The Mumbai Airport 90 year-old donates Rs. 1 lakh towards Aapda Rahat Kosh Employees of SBI Himachal Pradesh donate Rs. 77,29,825 towards relief fund Gaddi Jaandi Ae Chalaangaan Maardi Review: Comedic Brilliance Unleashed With A Heartfelt Wake Up Call For All CM Sukhvinder Singh Sukhu invites Himachali Diaspora in the UAE to invest in state's green sector Women reservation bill is a game changer for women empowerment: Devender Singh Rana Lt Governor addresses Utthan Foundation Trust’s seminar at Ghazipur; pays tributes to Pandit Deendayal Upadhyaya DTTM CUJ organises Travelism 2023 to mark World Tourism Day World Tourism Day 2023 Celebrated with Enthusiasm in District Kishtwar On World Tourism Day, Director Rural Sanitation visits J&K’s historic ‘Chhota Kashi’ DC Udhampur Saloni Rai Reviews Progress of Jal Jeevan Mission Works in Udhampur district Tourism Directorate Jammu Celebrates World Tourism Day with Heritage, Adventure and Sustainability at Mubarak Mandi Heritage complex DC Udhampur Saloni Rai presides over weekly Block Diwas at Panchayat Barta-Udhampur Seminar on Emerging Technologies in Solar Energy held at Polytechnic Jammu


New drug to stop deadly brain cancer from worsening shows promise

Health, Study, New York, Research, Researchers, World News, Cloughesy
Listen to this article

Web Admin

Web Admin

5 Dariya News

New York , 05 Jun 2023

The first clinical trial analysing a targeted therapy drug specifically developed to treat deadly brain cancer has shown that it can extend the amount of time people with glioma are on treatment without their cancer worsening.The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumour.

Researchers from the University of California-Los Angeles found the drug vorasidenib, manufactured by French drug company Servier Pharmaceuticals, more than doubled progression-free survival in people with recurrent grade 2 glioma.

Compared with people who received a placebo, people who took vorasidenib went for nearly 17 more months without their cancer worsening, delaying the time before they needed to begin chemotherapy and radiation.

The results of the trial were published in the New England Journal of Medicine and were also presented at the ongoing annual meeting of the American Society Clinical Oncology in Chicago, US.The type of glioma studied in the paper, recurrent grade 2 glioma with IDH1 and IDH2 mutations, tends to affect younger people, often those in their 30s.

The current standard treatment, a combination of radiation and chemotherapy, can cause neurological deficits that make it hard for patients to learn, remember new things, concentrate or make everyday decisions -- all of which can be especially challenging for people who have young families or are in the early years of their professional lives.

According to Dr Timothy Cloughesy, Professor of neuro-oncology at the David Geffen School of Medicine at UCLA, the availability of a treatment that enables patients to go for longer periods of time between chemotherapy and radiation treatments could have a major impact.

"We're always concerned about the delayed effects of radiation," said Cloughesy. "Having the ability to hold off on getting radiation therapy to the brain with effective therapy is really critical and very meaningful to this population of patients."

Vorasidenib is a brain-penetrant inhibitor, which means that it has the ability to cross the blood-brain barrier. The drug has not yet been approved by the US FDA for clinical use.The study involved 331 people aged 12 and older who had been diagnosed with recurrent grade 2 glioma with the IDH1 and IDH2 mutations and who had undergone brain tumour surgery. 

From that group, 168 were randomly assigned to receive vorasidenib and 163 received placebos.The disease progressed in just 28 per cent of people receiving vorasidenib, compared to 54 per cent of those receiving placebos. 

And as of September 2022, which was 30 months after the study began, 72 per cent of patients who were in the vorasidenib group were still taking the drug and their disease had not progressed."This is the first targeted treatment that shows unequivocal efficacy in this population and is precedent-setting for this disease," Cloughesy said.


Tags: Health , Study , New York , Research , Researchers , World News , Cloughesy



related news




Photo Gallery



Video Gallery



5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2023 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD